(Q44833296)

6 December 2017

title

Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

6 December 2017

main subject

1 reference

1 reference

Bulent Okan Yildiz

4

1 reference

ORCID Public Data File 2021

author name string

Ayla Harmanci

series ordinal

1

1 reference

6 December 2017

Nese Cinar

series ordinal

2

1 reference

6 December 2017

Miyase Bayraktar

series ordinal

3

1 reference

6 December 2017

language of work or name

1 reference

1 January 2013

1 reference

6 December 2017

published in

Clinical Endocrinology

1 reference

6 December 2017

volume

78

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

120-125

1 reference

The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Inflammatory markers and the risk of coronary heart disease in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Oral contraceptives use and the risk of myocardial infarction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Assessment, diagnosis and treatment of a patient with hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Assessment of glucose intolerance and insulin sensitivity in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Oral contraceptive use and increased plasma concentration of C-reactive protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

Effects of a beta blocker and spironolactone on plasma homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04466.X

10.1111/J.1365-2265.2012.04466.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference